ESMO 2023: Could BioNTech’s BNT211 Break Out Of The CAR-T Solid Tumor Cage?

The German biotech presented updated data at ESMO showing strong efficacy in ovarian cancer and other solid tumors, albeit with a higher degree of adverse events, particularly cytokine release syndrome.